Designing a prototype spike protein vaccine for SARS-CoV-2
A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.
No hay comentarios:
Publicar un comentario